Across TCGA pan-cancer cohorts, ERO1A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ERO1A data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ERO1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERO1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUSC, and UCEC are the cancer types where ERO1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.187	0.697	.001	45	view →
LUSC	OS	Median	All	0.140	0.762	<.001	36	view →
UCEC	OS	Median	All	0.964	0.658	.032	10	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ERO1A tumor-vs-normal RNA expression · all ERO1A data types